Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single center, phase I trial to evaluate the safety and efficacy of
toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal
carcinoma.